Home › Companies › COHERUS BIOSCIENCES INC. › 2023-2024

COHERUS BIOSCIENCES INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and COHERUS BIOSCIENCES INC.’s Form 8-K, filed June 4, 2024 (Item 5.07 on EDGAR). Page generated November 1, 2026.

6Ballot items
142Asset managers
864Fund votes
May 29, 2024Meeting date

Results at a glance

Meeting of May 29, 2024: 6 items on COHERUS BIOSCIENCES INC.’s Form 8-K, filed June 4, 2024: 3 elected · 3 approved.

Material dissent

Elect Director: Kimberly J. Tzoumakas 79% of votes cast Elected Director under 80%
4. The amendment and restatement of the Company's 2014 Equity Incentive Award Plan 67% of votes cast Approved Under 80%

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore COHERUS BIOSCIENCES INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by COHERUS BIOSCIENCES INC.

These tallies are COHERUS BIOSCIENCES INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 4, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

COHERUS BIOSCIENCES INC. — official shareholder meeting results, meeting held May 29, 2024
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Lee N. Newcomer, MD	48,281,843	--	--	10,274,659	--	82%	Elected	—
Elect Director: Charles W. Newton	47,197,934	--	--	11,358,568	--	81%	Elected	—
Elect Director: Kimberly J. Tzoumakas	46,098,866	--	--	12,457,636	--	79%	Elected	—
2. The selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024	79,827,737	551,990	147,169	--	0	99.3%	Approved	—
3. A non-binding, advisory resolution to approve the compensation of the Company's named executive officers (a "Say-on-Pay" vote)	40,280,182	16,457,046	1,819,274	--	21,970,394	71%	Approved	—
4. The amendment and restatement of the Company's 2014 Equity Incentive Award Plan	37,628,123	18,905,881	2,022,498	--	21,970,394	67%	Approved	—

Source: COHERUS BIOSCIENCES INC., Form 8-K, filed with the SEC on June 4, 2024 — read the filing on EDGAR.

How asset managers voted at the COHERUS BIOSCIENCES INC. 2023-2024 meeting

Each item below shows how the 142 asset managers that disclosed a COHERUS BIOSCIENCES INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Charles W. Newton

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 5 wordings of this item as funds reported it.

81% Majority: yes · of votes cast

FOR 81%WITHHELD

FOR: 47,197,934WITHHELD: 11,358,568

Details: description as filed, official tally, votes by 41 asset managers

Description as filed by funds: To elect three Class I directors to hold office until the 2027 Annual Meeting of Stockholders or until their successors are elected: Charles W. Newton

COHERUS BIOSCIENCES INC.’s own tally for this item (“Elect Director: Charles W. Newton”): 47,197,934 for, 11,358,568 withheld, per its Form 8-K filed June 4, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected by a majority of votes cast each of the Class I director nominees below, Lee N. Newcomer, MD, Charles W. Newton and Kimberly J. Tzoumakas, to the Board to hold office until the 2027 annual meeting of stockholders or until their successors are elected.”
Support: 81% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 41 asset managers below reported 10,337,275 for, 137,264 withheld.

FOR

FOR: 10,337,275WITHHOLD: 137,264

Largest asset managers voting on “To elect three Class I directors to hold office until the 2027 Annual Meeting of Stockholders or until their s” at COHERUS BIOSCIENCES INC., 2023-2024
Asset manager	For	Withheld	Vote
Vanguard	5,847,313	0	For
BlackRock	1,605,551	0	For
Delaware/Macquarie	900,000	0	For
Charles Schwab	689,456	0	For
BRIDGEWAY FUNDS INC	168,000	0	For
Equitable	164,003	0	For
New York Life	154,248	0	For
SEI	151,620	0	For
QUANTITATIVE MASTER SERIES LLC	125,858	0	For
Fidelity	110,917	0	For
MFS	98,019	0	For
Lincoln Financial	0	83,905	Withhold
Northern Trust	65,347	0	For
John Hancock	38,068	0	For
Pacific Life	33,880	0	For
Transamerica	31,088	0	For
Brighthouse	1	29,534	Withhold
ProShares	26,494	0	For
Bridge Builder Trust	23,391	0	For
Principal Exchange-Traded Funds	14,995	0	For
DWS	14,337	0	For
Principal	14,075	0	For
Victory Capital	13,979	0	For
AIG/SunAmerica	13,430	0	For
Voya	12,075	0	For

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

2. Elect Director: Kimberly J. Tzoumakas

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 5 wordings of this item as funds reported it.

79% Majority: yes · of votes cast

FOR 79%WITHHELD

FOR: 46,098,866WITHHELD: 12,457,636

Details: description as filed, official tally, votes by 41 asset managers

Description as filed by funds: To elect three Class I directors to hold office until the 2027 Annual Meeting of Stockholders or until their successors are elected: Kimberly J. Tzoumakas

COHERUS BIOSCIENCES INC.’s own tally for this item (“Elect Director: Kimberly J. Tzoumakas”): 46,098,866 for, 12,457,636 withheld, per its Form 8-K filed June 4, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected by a majority of votes cast each of the Class I director nominees below, Lee N. Newcomer, MD, Charles W. Newton and Kimberly J. Tzoumakas, to the Board to hold office until the 2027 annual meeting of stockholders or until their successors are elected.”
Support: 79% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 41 asset managers below reported 10,120,373 for, 354,166 withheld.

FOR

FOR: 10,120,373WITHHOLD: 354,166

Largest asset managers voting on “To elect three Class I directors to hold office until the 2027 Annual Meeting of Stockholders or until their s” at COHERUS BIOSCIENCES INC., 2023-2024
Asset manager	For	Withheld	Vote
Vanguard	5,847,313	0	For
BlackRock	1,605,551	0	For
Delaware/Macquarie	900,000	0	For
Charles Schwab	689,456	0	For
BRIDGEWAY FUNDS INC	0	168,000	Withhold
Equitable	17,503	146,500	Mixed
New York Life	154,248	0	For
SEI	151,620	0	For
QUANTITATIVE MASTER SERIES LLC	125,858	0	For
Fidelity	110,917	0	For
MFS	98,019	0	For
Lincoln Financial	83,905	0	For
Northern Trust	65,347	0	For
John Hancock	38,068	0	For
Pacific Life	33,880	0	For
Transamerica	31,088	0	For
Brighthouse	1	29,534	Withhold
ProShares	26,494	0	For
Bridge Builder Trust	23,391	0	For
Principal Exchange-Traded Funds	14,995	0	For
DWS	14,337	0	For
Principal	14,075	0	For
Victory Capital	13,979	0	For
AIG/SunAmerica	13,430	0	For
Voya	12,075	0	For

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

3. Elect Director: Lee N. Newcomer, MD

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 5 wordings of this item as funds reported it.

82% Majority: yes · of votes cast

FOR 82%WITHHELD

FOR: 48,281,843WITHHELD: 10,274,659

Details: description as filed, official tally, votes by 41 asset managers

Description as filed by funds: To elect three Class I directors to hold office until the 2027 Annual Meeting of Stockholders or until their successors are elected: Lee N. Newcomer, MD

COHERUS BIOSCIENCES INC.’s own tally for this item (“Elect Director: Lee N. Newcomer, MD”): 48,281,843 for, 10,274,659 withheld, per its Form 8-K filed June 4, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected by a majority of votes cast each of the Class I director nominees below, Lee N. Newcomer, MD, Charles W. Newton and Kimberly J. Tzoumakas, to the Board to hold office until the 2027 annual meeting of stockholders or until their successors are elected.”
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 41 asset managers below reported 10,434,876 for, 39,663 withheld.

FOR

FOR: 10,434,876WITHHOLD: 39,663

Largest asset managers voting on “To elect three Class I directors to hold office until the 2027 Annual Meeting of Stockholders or until their s” at COHERUS BIOSCIENCES INC., 2023-2024
Asset manager	For	Withheld	Vote
Vanguard	5,847,313	0	For
BlackRock	1,605,551	0	For
Delaware/Macquarie	900,000	0	For
Charles Schwab	689,456	0	For
BRIDGEWAY FUNDS INC	168,000	0	For
Equitable	164,003	0	For
New York Life	154,248	0	For
SEI	151,620	0	For
QUANTITATIVE MASTER SERIES LLC	125,858	0	For
Fidelity	110,917	0	For
MFS	98,019	0	For
Lincoln Financial	83,905	0	For
Northern Trust	65,347	0	For
John Hancock	38,068	0	For
Pacific Life	33,880	0	For
Transamerica	31,088	0	For
Brighthouse	1	29,534	Withhold
ProShares	26,494	0	For
Bridge Builder Trust	23,391	0	For
Principal Exchange-Traded Funds	14,995	0	For
DWS	14,337	0	For
Principal	14,075	0	For
Victory Capital	13,979	0	For
AIG/SunAmerica	13,430	0	For
Voya	12,075	0	For

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

4. 4. The amendment and restatement of the Company's 2014 Equity Incentive Award Plan

Official resultCOMPENSATIONReported outcome: Approved

Combines 5 wordings of this item as funds reported it.

67% Approved · of votes cast

FOR 67%AGAINST

FOR: 37,628,123AGAINST: 18,905,881

Details: description as filed, official tally, votes by 42 asset managers

Description as filed by funds: To approve the amendment and restatement of the Company's 2014 Equity Incentive Award Plan (the "2014 Plan").

COHERUS BIOSCIENCES INC.’s own tally for this item (“4. The amendment and restatement of the Company's 2014 Equity Incentive Award Plan”): 37,628,123 for, 18,905,881 against — passed, per its Form 8-K filed June 4, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the amendment and restatement of the Company's 2014 Equity Incentive Award Plan.”
Support: 67% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 9,596,383 for, 1,847,396 against, 29,534 abstained.

FORAGAINST

FOR: 9,596,383AGAINST: 1,847,396ABSTAIN: 29,534

Largest asset managers voting on “To approve the amendment and restatement of the Company's 2014 Equity Incentive Award Plan (the "2014 Plan").” at COHERUS BIOSCIENCES INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	5,847,313	0	0	For
BlackRock	1,605,551	0	0	For
MUTUAL FUND SERIES TRUST	1,000,000	0	0	For
Delaware/Macquarie	0	900,000	0	Against
Charles Schwab	689,456	0	0	For
BRIDGEWAY FUNDS INC	0	168,000	0	Against
Equitable	17,503	146,500	0	Mixed
New York Life	0	154,248	0	Against
SEI	151,620	0	0	For
QUANTITATIVE MASTER SERIES LLC	125,858	0	0	For
Fidelity	91,739	19,178	0	Mixed
MFS	0	98,019	0	Against
Lincoln Financial	0	83,905	0	Against
Northern Trust	0	65,347	0	Against
John Hancock	0	38,068	0	Against
Pacific Life	33,880	0	0	For
Transamerica	0	31,088	0	Against
Brighthouse	0	1	29,534	Abstain
ProShares	0	26,494	0	Against
Bridge Builder Trust	23,391	0	0	For
Principal Exchange-Traded Funds	0	14,995	0	Against
DWS	0	14,337	0	Against
Principal	0	14,075	0	Against
Victory Capital	0	13,979	0	Against
AIG/SunAmerica	0	13,430	0	Against

Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.

5. 3. A non-binding, advisory resolution to approve the compensation of the Company's named executive officers (a…

Official result Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 16 wordings of this item as funds reported it.

71% Approved · of votes cast

FOR 71%AGAINST

FOR: 40,280,182AGAINST: 16,457,046

Details: description as filed, official tally, votes by 142 asset managers

Description as filed by funds: To vote on a non-binding, advisory basis to approve the compensation of the Company's named executive officers (a "Say-on-Pay" vote).

COHERUS BIOSCIENCES INC.’s own tally for this item (“3. A non-binding, advisory resolution to approve the compensation of the Company's named executive officers (a "Say-on-Pay" vote)”): 40,280,182 for, 16,457,046 against — passed, per its Form 8-K filed June 4, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved a non-binding, advisory resolution to approve the compensation of the Company's named executive officers (a "Say-on-Pay" vote).”
Support: 71% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 41 asset managers voting on “To vote on a non-binding, advisory basis to approve the compensation of the Company's named executive officers” at COHERUS BIOSCIENCES INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	5,847,313	0	0	For
BlackRock	1,605,551	0	0	For
MUTUAL FUND SERIES TRUST	1,000,000	0	0	For
Delaware/Macquarie	900,000	0	0	For
Charles Schwab	689,456	0	0	For
BRIDGEWAY FUNDS INC	0	168,000	0	Against
Equitable	164,003	0	0	For
New York Life	154,248	0	0	For
SEI	151,620	0	0	For
QUANTITATIVE MASTER SERIES LLC	125,858	0	0	For
Fidelity	110,917	0	0	For
MFS	98,019	0	0	For
Lincoln Financial	83,905	0	0	For
Northern Trust	65,347	0	0	For
John Hancock	38,068	0	0	For
Pacific Life	33,880	0	0	For
Transamerica	31,088	0	0	For
Brighthouse	1	0	29,534	Abstain
ProShares	26,494	0	0	For
Bridge Builder Trust	23,391	0	0	For
Principal Exchange-Traded Funds	14,995	0	0	For
DWS	14,337	0	0	For
Principal	14,075	0	0	For
Victory Capital	13,979	0	0	For
AIG/SunAmerica	13,430	0	0	For

Fund voting reports, all 41 managers: 11,261,989 for, 181,690 against, 29,534 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 115 asset managers voting on “To vote on a non-binding, advisory basis to approve the compensation of the Company's named executive officers” at COHERUS BIOSCIENCES INC., 2023-2024
Asset manager	For	Against	Vote
Rubric Capital Management LP	0	8,307,399	Against
Temasek Holdings (Private) Ltd	7,381,116	0	For
BlackRock	2,130,893	776	For
C WorldWide Asset Management Fondsmaeglerselskab A/S	0	1,928,464	Against
Kohlberg Kravis Roberts & Co. L.P.	1,499,499	0	For
State Street	1,071,264	368	For
DISCIPLINED GROWTH INVESTORS INC /MN	0	1,068,751	Against
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST	900,000	0	For
Citadel	831,593	0	For
Charles Schwab	822,338	0	For
Clearline Capital LP	784,449	0	For
PEREGRINE CAPITAL MANAGEMENT LLC	772,341	0	For
Woodline Partners LP	684,948	0	For
Two Sigma	498,032	0	For
Hudson Bay Capital Management LP	496,573	0	For
Northern Trust	460,578	54	For
Lazard	387,700	0	For
MELLON INVESTMENTS Corp	326,479	0	For
Vanguard	325,674	0	For
Wellington	305,879	0	For
Birchview Capital, LP	256,000	0	For
Goldman Sachs	194,038	0	For
BRIDGEWAY CAPITAL MANAGEMENT, LLC	0	168,000	Against
SEI	152,007	76	For
AllianceBernstein	146,500	0	For

Institutional-manager reports, all 115 managers: 21,683,010 for, 11,582,619 against. Showing the 25 largest; see all in the interactive database.

6. 2. The selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

99.3% Approved · of votes cast

FOR 99.3%

FOR: 79,827,737AGAINST: 551,990

Details: description as filed, official tally, votes by 42 asset managers

Description as filed by funds: To ratify the selection, by the Audit Committee of our Board of Directors, of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.

COHERUS BIOSCIENCES INC.’s own tally for this item (“2. The selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024”): 79,827,737 for, 551,990 against — passed, per its Form 8-K filed June 4, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.”
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 11,444,695 for, 310 against, 29,534 abstained.

FOR

FOR: 11,444,695AGAINST: 310ABSTAIN: 29,534

Largest asset managers voting on “To ratify the selection, by the Audit Committee of our Board of Directors, of Ernst & Young LLP as our indepen” at COHERUS BIOSCIENCES INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	5,847,313	0	For
BlackRock	1,605,551	0	For
MUTUAL FUND SERIES TRUST	1,000,000	0	For
Delaware/Macquarie	900,000	0	For
Charles Schwab	689,456	0	For
BRIDGEWAY FUNDS INC	168,000	0	For
Equitable	164,003	0	For
New York Life	154,248	0	For
SEI	151,620	0	For
QUANTITATIVE MASTER SERIES LLC	125,858	0	For
Fidelity	110,917	0	For
MFS	98,019	0	For
Lincoln Financial	83,905	0	For
Northern Trust	65,347	0	For
John Hancock	38,068	0	For
Pacific Life	33,880	0	For
Transamerica	31,088	0	For
Brighthouse	1	29,534	Abstain
ProShares	26,494	0	For
Bridge Builder Trust	23,391	0	For
Principal Exchange-Traded Funds	14,995	0	For
DWS	14,337	0	For
Principal	14,075	0	For
Victory Capital	13,979	0	For
AIG/SunAmerica	13,430	0	For

Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.

Largest COHERUS BIOSCIENCES INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 114,725,740 shares outstanding at the time of that meeting.

Fund voting reports: top COHERUS BIOSCIENCES INC. shareholders by shares voted on “To vote on a non-binding, advisory basis to approve the compensation of the Company's named…”, 2023-2024
#	Asset manager	% of shares outstanding
1	Vanguard	5.10%
2	BlackRock	1.40%
3	MUTUAL FUND SERIES TRUST	0.87%
4	Delaware/Macquarie	0.78%
5	Charles Schwab	0.60%
6	BRIDGEWAY FUNDS INC	0.15%
7	Equitable	0.14%
8	New York Life	0.13%
9	SEI	0.13%
10	QUANTITATIVE MASTER SERIES LLC	0.11%

Institutional-manager reports: top COHERUS BIOSCIENCES INC. shareholders by shares voted on “To vote on a non-binding, advisory basis to approve the compensation of the Company's named…”, 2023-2024
#	Asset manager	% of shares outstanding
1	Rubric Capital Management LP	7.24%
2	Temasek Holdings (Private) Ltd	6.43%
3	BlackRock	1.86%
4	C WorldWide Asset Management Fondsmaeglerselskab A/S	1.68%
5	Kohlberg Kravis Roberts & Co. L.P.	1.31%
6	State Street	0.93%
7	DISCIPLINED GROWTH INVESTORS INC /MN	0.93%
8	MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST	0.78%
9	Citadel	0.72%
10	Charles Schwab	0.72%

Reported COHERUS BIOSCIENCES INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

COHERUS BIOSCIENCES INC. holdings and ownership disclosed for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
BlackRock	9.12%	13F
Vanguard Group	9.00%	13F
Entities associated with Temasek Holdings (Private) Limited	6.43%	DEF14A
Ali J. Satvat	2.65%	DEF14A
Citadel Advisors	2.50%	13F
Geode Capital	1.92%	13F
State Street	1.74%	13F
Two Sigma	1.27%	13F
Millennium Management	1.10%	13F
Dennis M. Lanfear	1.07%	DEF14A

Percentages above are of 114,725,740 shares outstanding, as reported by COHERUS BIOSCIENCES INC. on its Form 10-Q dated April 30, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from COHERUS BIOSCIENCES INC.’s 10-Q dated April 30, 2024. This page is a static snapshot rebuilt weekly on November 1, 2026; a live search always shows the current data.

At COHERUS BIOSCIENCES INC.'s shareholder meeting held May 29, 2024, in the 2023-2024 proxy season, 142 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 864 separate fund positions. On the most widely held item on that ballot — To vote on a non-binding, advisory basis to approve the compensation of the Company's named… — COHERUS BIOSCIENCES INC.'s filing reports the proposal as approved, with 71% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: COHERUS BIOSCIENCES INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 4, 2024.

COHERUS BIOSCIENCES INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.